VJHemOnc Podcast iwAL 2022 Session IV: the evolving treatment landscape in ALL and the growing role of immunotherapies
Nov 22, 2022
Experts discuss the evolving treatment landscape in ALL and the role of immunotherapies like ADCs and CAR-T cells. They highlight the potential of targeted therapy and stopping therapy in pH positive ALL. The efficacy of cartizo for CNS infiltration and combination therapy for non-CNS EMD is discussed. The use of immunotherapies in ALL treatment is explored, including the benefits of combining therapies and optimizing immunotherapy. The effects of treatments on the immune system and tumor microenvironment in ALL are examined, including Punatine's impact on T-cells and NK-cells and the potential of LCK inhibition.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
The Evolving Treatment Landscape in pH Positive ALL and the Role of Immunotherapies
02:18 • 2min
Efficacy of Cartizo for CNS Infiltration and Combination Therapy for Non-CNS EMD
03:58 • 3min
Immunotherapies in the Treatment of Acute Lymphoblastic Leukemia
07:13 • 6min
The Effects of Treatments on the Immune System and Tumor Microenvironment in ALL
13:24 • 3min